Variables Period Placebo group (n=21) Intervention group (n=22) MD (95% CI‡,) between groups
FPG (mg/dL) Initial 99.70 (5.30) 98.32 (4.06) -1.40 (- 1.50 to 4.30)
End 101.22 (5.15) 97.60 (7.30) -3.63 (-0.30 to 7.50)#
MD (95% CI) within groups 1.50 (-3.50 to 0.50) -0.73 (-2.30 to 3.70)
Insulin (μU/ml) Initial 10.70 ( 2.60) 10.50 (4.20) -0.17 (-2.00 to 2.36)
End 10.06 (1.99) 8.30 (2.66) a,b -1.76 (-3.22 to -0.31)
MD (95% CI) within groups -0.62 (-0.04 to 1.21) -2.22 (-0.55 to 3.90)
HOMA-IR Initial 2.64 (0.70) 2.55 (1.05) -0.09 (-0.46 to 0.64)
End 2.50 (0.50) 2.00 (0.70)b -0.50 (-0..90 to -0.13)
MD (95% CI) within groups -0.13 (-0. 04 to 0.30) -0.55 (-0.13 to -0.96)
QUICK Initial 3.01 (0.12) 2.98 (0.17) -0.03 (-0.06 to 0.12)
End 3.00 (0.85) 2.87 (0.17) a -0.15 (-0.03 to 0.21)
MD (95% CI) within groups -0.01 (-0.01- to 0.05) -0.11 (-0.03 to -0.17)
hs-CRP (ng/ml) Initial 11.40 (3.15) 10.88 (3.50) -0.50 (-1.49 to 2.55)
End 9.50 (2.49) 8.27 (1.65) a, b -1.25 (-2.5 to -0.47)
MD (95% CI) within groups -1.90 (-0.65 to 3.25)a -2.60 (-1.30 to -3.93)
LPS (EU/ml) Initial 19.59 (6.25) 16.60 (6.60) -2.99 (-1.60 to 10.36)
End 18.46 (7.90) 12.45 (6.25)a,b -5.59 (-1.61 to -10.36)
MD (95% CI) within groups -1.15 (-0.52 to 2.75) -4.10 (-2.35 to -5.80)